BackCRISPR Therapeutics AG Overview

CRISPR Therapeutics AG Total Liabilities

Track CRISPR Therapeutics AG's total liabilities ($910M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$911.26M
170.45% YoYΔ $574.32M vs prior year quarter

Peer average

Loading

CRISPR Therapeutics AG Total Liabilities History

Loading

CRISPR Therapeutics AG vs. peers: Total Liabilities Comparison

Loading

CRISPR Therapeutics AG Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CRISPR Therapeutics AG (CRSP) FAQ

As of the most recent data (March 2026), CRSP shows a total liabilities of $910M. That compares with $340M in the prior-year period — up 170.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CRSP's total liabilities is now $910M (was $340M) — a 170.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether CRISPR Therapeutics AG is outperforming or lagging.

Tracking CRSP's total liabilities over time shows whether CRISPR Therapeutics AG is scaling, shrinking, or reshaping that part of the business. The current reading is $910M That compares with $340M in the prior-year period — up 170.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total liabilities page, Stockcircle has CRISPR Therapeutics AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total liabilities (currently $910M) with ownership activity and broader fundamentals.

CRISPR Therapeutics AG's total liabilities is $910M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.